VAXX - Vaxxinity, Inc. Stock Price, Fair Value and News

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VAXX Price Action

Last 90 days

-100%

Trailing 12 Months

-100%

VAXX RSI Chart

VAXX Valuation

EV/EBITDA

0.09

VAXX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VAXX Fundamentals

VAXX Revenue

Revenue (TTM)

66.0K

VAXX Earnings

Earnings (TTM)

-56.9M

VAXX Profitability

Operating Margin

100.00%

EBT Margin

-86263.64%

Return on Equity

-424.6%

Return on Assets

-128.49%

VAXX Investor Care

Shares Dilution (1Y)

0.57%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	434.3K	311.5K	188.8K	66.0K
2020	0	0	0	557.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

CEO	Ms. Mei Mei Hu J.D.
WEBSITE	vaxxinity.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	87

Vaxxinity, Inc. Frequently Asked Questions

What is the ticker symbol for Vaxxinity, Inc.? What does VAXX stand for in stocks?

VAXX is the stock ticker symbol of Vaxxinity, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxxinity, Inc. (VAXX)?

As of Fri Dec 20 2024, market cap of Vaxxinity, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VAXX stock?

You can check VAXX's fair value in chart for subscribers.

Is Vaxxinity, Inc. a good stock to buy?

The fair value guage provides a quick view whether VAXX is over valued or under valued. Whether Vaxxinity, Inc. is cheap or expensive depends on the assumptions which impact Vaxxinity, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VAXX.

What is Vaxxinity, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, VAXX's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VAXX PE ratio will change depending on the future growth rate expectations of investors.